TY - JOUR
T1 - Targeting Sirtuin-1 in Huntington's disease
T2 - Rationale and current status
AU - Duan, Wenzhen
N1 - Funding Information:
Acknowledgments The author acknowledges grants NS074196 and NS072344 from the National Institutes of Health, CHDI A3875, Hereditary Disease Foundation, which supported preparation of this manuscript and some of the research reported herein. The author declares no conflicts of interest in writing this article.
PY - 2013/5
Y1 - 2013/5
N2 - Huntington's disease (HD) is an autosomal dominant hereditary disease caused by a trinucleotide repeat mutation in the huntingtin gene that results in an increased number of glutamine residues in the N terminus of huntingtin protein. Mutant huntingtin leads to progressive impairment of motor function, cognitive dysfunction, and neuropsychiatric disturbance. There are no disease-modifying treatments available. During the past decade, sirtuin-1 (SIRT1) has been the focus of intense investigation and discussion because it regulates longevity in multiple organisms and has shown beneficial effects in a variety of models of neurodegenerative disorders. Studies in different animal models provide convincing evidence that SIRT1 protects neurons in mouse models of HD as well as in Caenorhabditis elegans, although controversial results were reported in a fly model. Indeed, many connections exist between the deacetylation function of SIRT1 and its role in neuroprotection. As a result, pharmacological interventions targeting SIRT1 might become promising strategies to combat HD. This review summarizes recent progress in SIRT1 research, with a focus on the specificity of this protein as a potential therapeutic target for HD, as well as existing challenges for developing SIRT1 modulators for clinical use.
AB - Huntington's disease (HD) is an autosomal dominant hereditary disease caused by a trinucleotide repeat mutation in the huntingtin gene that results in an increased number of glutamine residues in the N terminus of huntingtin protein. Mutant huntingtin leads to progressive impairment of motor function, cognitive dysfunction, and neuropsychiatric disturbance. There are no disease-modifying treatments available. During the past decade, sirtuin-1 (SIRT1) has been the focus of intense investigation and discussion because it regulates longevity in multiple organisms and has shown beneficial effects in a variety of models of neurodegenerative disorders. Studies in different animal models provide convincing evidence that SIRT1 protects neurons in mouse models of HD as well as in Caenorhabditis elegans, although controversial results were reported in a fly model. Indeed, many connections exist between the deacetylation function of SIRT1 and its role in neuroprotection. As a result, pharmacological interventions targeting SIRT1 might become promising strategies to combat HD. This review summarizes recent progress in SIRT1 research, with a focus on the specificity of this protein as a potential therapeutic target for HD, as well as existing challenges for developing SIRT1 modulators for clinical use.
UR - http://www.scopus.com/inward/record.url?scp=84878573777&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84878573777&partnerID=8YFLogxK
U2 - 10.1007/s40263-013-0055-0
DO - 10.1007/s40263-013-0055-0
M3 - Article
C2 - 23549885
AN - SCOPUS:84878573777
SN - 1172-7047
VL - 27
SP - 345
EP - 352
JO - CNS Drugs
JF - CNS Drugs
IS - 5
ER -